Inhibitors of JAK2 and JAK3: An update on the patent literature 2010-2012

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 4, 2013, Pages 449-501

  Dymock, Brian W ^a   See, Cheng Shang ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

JAK; JAK2 inhibitor; JAK3 inhibitor; Janus kinase inhibitors; Myeloproliferative neoplasms; Oncology; Rheumatoid arthritis; Ruxolitinib; Tofacitinib

Indexed keywords

2 AMINO 5[1,2,4]TRIAZOLO[1,5 A]PYRIDINE DERIVATIVE; 3 AMIDOINDAZOLE DERIVATIVE; 3 AMINO 4 CARBOXAMIDOPYRAZOLE DERIVATIVE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; [1,2,4]TRIAZOLO[1,5 A]PYRIDINE DERIVATIVE; AMINOMETHYLTHIAZOLE; BARICITINIB; BMS 911543; CEP 33779; CP 690500; CYANO 2 PYRIDYL DERIVATIVE; DIAMINOPYRIMIDINE DERIVATIVE; DIPHENYLPYRROLO[1,2 F][1,2,4]TRIAZIN 2 AMINE DERIVATIVE; GANDOTINIB; GLPG 0634; GSK 2586184; IMIDAZO[4,5 C]PYRROLO[2,3 B]PYRIDINE DERIVATIVE; ISOQUINAZOLINE DERIVATIVE; JANUS KINASE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; LESTAURTINIB; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NS 018; PACRITINIB; PRT 2070; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; PYRROLO[1,2 F][1,2,4]TRIAZINE DERIVATIVE; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RUXOLITINIB; SB 1317; SB 1578; THIENO[2,3 D]PYRIMIDINE DERIVATIVE; TOFACITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 509;

ACUTE LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INFLAMMATION; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG AND NARCOTIC CONTROL; HUMANS; JANUS KINASE 2; JANUS KINASE 3; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875182662     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.765862     Document Type: Review

References (188)

1. Vakil E, Tefferi A. BCR-ABL1-negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk 2011;11(Suppl 1):S37-45
2. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors 2012;30(2):88-106
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365(9464):1054-61
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-8
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352(17):1779-90
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7(4):387-97
7. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807
8. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
9. Leah E. Clinical trials: phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis. Nat Rev Rheumatol 2012;8(10):561
10. Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol 2011;29(6):467-8
11. FDA approves Xeljanz for rheumatoid arthritis. 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm [Last accessed November 2012]
12. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36(4):503-14
13. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin cell Dev Biol 2008;19(4):414-22
14. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93(3):373-83
15. Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93(3):397-409
16. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93(3):385-95
17. Samanta AK, Lin H, Sun T, et al. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006;66(13):6468-72
18. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377(6544):65-8
19. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270(5237):797-800
20. Suzuki K, Nakajima H, Saito Y, et al. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol 2000;12(2):123-32
21. Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Nat Acad Sci USA 2003;100(20):11594-9
22. Ishizaki M, Akimoto T, Muromoto R, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol 2011;187(1):181-9
23. Prchal-Murphy M, Semper C, Lassnig C, et al. TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS One 2012;7(6):e39141
24. Ishizaki M, Muromoto R, Akimoto T, et al. Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Int Immunol 2011;23(9):575-82
25. Norman P. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert Opin Ther Pat 2012;22(10):1233-49
26. Kiss R, Sayeski PP, Keseru GM. Recent developments on JAK2 inhibitors: a patent review. Expert Opin Ther Pat 2010;20(4):471-95
27. Wilson LJ. Recent patents in the discovery of small molecule inhibitors of JAK3. Expert Opin Ther Pat 2010;20(5):609-23
28. Ambit Biosciences Corp. Quinoline and isoquinoline compounds and methods of use thereof. WO2012030944; 2012
29. Ambit Biosciences Corp. Azolopyridine and azolopyrimidine compounds and methods of use thereof. WO2012030924; 2012
30. Ambit Biosciences Corp. 4-azolylaminoquinazoline derivatives and methods of use thereof. WO2012030914; 2012
31. Ambit Biosciences Corp. 7-cyclylquinazoline derivatives and methods of use thereof. WO2012030912; 2012
32. Ambit Biosciences Corp. 2-cycloquinazoline derivatives and methods of use thereof. WO2012030910; 2012
33. Ambit Biosciences Corp. JAK kinase modulating quinazoline derivatives and methods of use thereof. WO2010099379; 2010
34. Ambit Biosciences Corp. Thienopyridine and thienopyrimidine compounds and methods of use thereof. WO2012030894; 2012
35. Ambit Biosciences Corp. JAK kinase modulating compounds and methods of use thereof. WO2010002472; 2010
36. Array Biopharma, Inc. 5,7-substitutedimidazo[ 1,2-c]pyrimidines as inhibitors of JAK kinases. WO2011130146; 2011
37. AstraZeneca AB. Heterocyclic JAK kinase inhibitors. WO2010038060; 2010
38. AstraZeneca AB. 2-(imidazolylamino)- pyridine derivatives and their use as JAK kinase inhibitors. WO2010020810; 2010
39. Bristol-Myers Squibb Co. JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer. WO2011028864; 2011
40. Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012;26(2):280-8
41. Clinical Trial of BMS-911543. 2012. Available from: http:// clinicaltrials. gov/ct2/show/NCT01236352? term=911543&rank=1 [Last accessed November 2012]
42. Cephalon, Inc. Preparation and uses of 1,2,4-triazolo[1,5-a]pyridine derivatives. WO2010141796; 2010
43. Dugan BJ, Gingrich DE, Mesaros EF, et al. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779. J Med Chem 2012;55(11):5243-54
44. Seavey MM, Lu LD, Stump KL, et al. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. Mol Cancer Ther 2012;11(4):984-93
45. Zificsak CA, Gingrich DE, Breslin HJ, et al. Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases. Bioorg Med Chem Lett 2012;22(1):133-7
46. Cephalon, Inc. Pyrrolotriazines as ALK and JAK2 inhibitors. WO2010071885; 2010
47. Weinberg LR, Albom MS, Angeles TS, et al. 2,7-Pyrrolo[2,1-f][1,2,4] triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation. Bioorg Med Chem Lett 2011;21(24):7325-30
48. SAR302503 in phase II studies for myelofibrosis. 2012. Available from: http://clinicaltrials. gov/ct2/show/NCT01420770? term=JAK&rank=17 [Last accessed November 2012]
49. SAR302503 trial for patients previously treated with Ruxolitinib. Available from: http://clinicaltrials.gov/ct2/show/NCT01523171?term= JAK&rank=33 [Last accessed November 2012]
50. Mesaros EF, Thieu TV, Wells GJ, et al. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4] triazines: identification of orally bioavailable, efficacious ALK inhibitors. J Med Chem 2012;55(1):115-25
51. Ott GR, Wells GJ, Thieu TV, et al. 2,7- disubstituted-pyrrolo[2,1-f][1,2, 4] triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. J Med Chem 2011;54(18):6328-41
52. Debiopharm SA. Bicyclic compounds and their uses as dual c-Src/JAK inhibitors. WO2011101806; 2011
53. Eli Lilly and Co. Amino pyrazole compound. US20100152181; 2010
54. Mitchell D, Cole KP, Pollock PM, et al. Development and a practical synthesis of the JAK2 inhibitor LY2784544. Org Proc Res Dev 2012;17:70-81
55. Galapagos NV. Novel compounds useful for the treatment of degenerative and inflammatory diseases (1). WO2010010191; 2010
56. Galapagos NV. Novel compounds useful for the treatment of degenerative and inflammatory diseases (2). WO2010010190; 2010
57. Galapagos NV. Novel compounds useful for the treatment of degenerative and inflammatory diseases (3). WO2010010189; 2010
58. Galapagos NV. Novel compounds useful for the treatment of degenerative and inflammatory diseases (4). WO2010010188; 2010
59. Galapagos NV. Novel compounds useful for the treatment of degenerative and inflammatory diseases (5). WO2010010187; 2010
60. Galapagos NV. Novel compounds useful for the treatment of degenerative and inflammatory diseases (6). WO2010010186; 2010
61. Galapagos NV. [1,2,4]triazolo[1,5-a] pyridines as JAK inhibitors. WO2010010184; 2010
62. Galapagos NV. 5-phenyl-[1,2,4]triazolo [1,5-a]pyridin-2-yl carboxamides as JAK inhibitors. WO2010149769; 2010
63. Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods. WO2010051549; 2010
64. Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods. WO2011003065; 2011
65. Hanan EJ, van Abbema A, Barrett K, et al. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. J Med Chem 2012;55(22):10090-107
66. Hutchison MediPharma Ltd. Pyrrolopyrimidine compounds and uses thereof (1). WO2012022045; 2012
67. Hutchison Medipharma Ltd. Pyrrolopyrimidine compounds and uses thereof (2). WO2012022265; 2012
68. Incyte Corp. Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors. WO2012068440; 2012
69. Incyte Corp. Process for preparing JAK inhibitors and related intermediate compounds. WO2010083283; 2010
70. Lin Q, Meloni D, Pan Y, et al. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett 2009;11(9):1999-2002
71. Incyte Corp. Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d] pyrimidines as Janus kinase inhibitors. WO2011028685; 2011
72. Incyte Corp. 3-[4-(7H-Pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl] octaneor heptane-nitrile as JAK inhibitors. WO2010135621; 2010
73. Incyte Corp. Janus kinase inhibitors for the treatment of dry eye and other eye related diseases. WO2010039939; 2010
74. Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology 2012;119(7):1328-35
75. Incyte Corp. Topical formulation for a JAK inhibitor. WO2011146808; 2011
76. Incyte Corp. Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors. WO2012068450; 2012
77. Incyte Corp. Cyclobutane and methylcyclobutane derivatives as janus kinase derivatives. WO2011103423; 2011
78. Incyte Corp. Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7Hpyrrolo[ 2,3-d]pyrimidin-4-yl)-1Hpyrazol- 1-yl]-3- cyclopentylpropanenitrile. WO2011044481; 2011
79. Incyte Corp. Macrocyclic compounds and their use as kinase inhibitors. WO2010085597; 2010
80. F. Hoffmann-La Roche AG. Macrocyclic inhibitors of JAK. WO2011033053; 2011
81. William AD, Lee AC, Blanchard S, et al. Discovery of the macrocycle 11-(2- pyrrolidin-1-yl-ethoxy)-14,19-dioxa- 5,7,26-triaza-tetracyclo[19.3.1.1(2, 6). 1 (8,12)]heptacosa-1(25),2(26),3,5,8,10,12 (27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 2011;54(13):4638-58
82. William AD, Lee AC, Poulsen A, et al. Discovery of the macrocycle (9E)-15-(2- (pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa- 19,21,24-triaza- tetracyclo[18. 3.1.1(2,5).1 (14,18)]hexacosa-1(24),2,4,9,14 (26),15,17,20,22- nonaene (SB1578), a potent inhibitor of janus kinase 2/fmslike tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis. J Med Chem 2012;55(6):2623-40
83. William AD, Lee AC, Goh KC, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa- 5,7,14,26-tetraazatetracyclo[19.3.1.1 (2,6).1(8,12)]heptaco sa-1(25),2 (26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem 2012;55(1):169-96
84. Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors. WO2011097525; 2011
85. Merck Sharp & Dohme Corp. Inhibitors of Janus kinases (2). WO2010014453; 2010
86. Merck Sharp & Dohme Corp. Inhibitors of Janus kinases (1). WO2010011375; 2010
87. Nerviano Medical Sciences. Substituted indazole derivatives active as kinase inhibitors. WO2010069966; 2010
88. Novartis Pharma AG. mTOR/JAK inhibitor combination therapy. WO2012112847; 2012
89. Pfizer, Inc. Pyrrolo[2,3-d]pyrimidine urea compounds as JAK inhibitors. WO2011097087; 2011
90. Pfizer, Inc. Beneficial effects of combination therapy on cholesterol. US20120252825; 2012
91. Pfizer, Inc. Pyrrolo[2,3-d]pyrimidine compounds. WO2010020905; 2010
92. Pfizer, Inc. Pyrrolo[2,3-d]pyrimidine compounds (2). WO2011075334; 2011
93. Pfizer, Inc. Pyrrolo[2,3-d]pyrimidine compounds (1). WO2011045702; 2011
94. Auspex Pharmaceuticals, LLC. Piperidine inhibitors of Janus Kinase 3. WO2010123919; 2010
95. Ratiopharm and Teva. Process for preparing tofacitinib salts. WO2012135338; 2012
96. Pfizer, Inc. Crystalline and non-crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer. WO2012137111; 2012
97. S*BIO Pte Ltd. Oxygen linked pyrimidine derivatives. WO2007058627; 2007
98. S*BIO Pte Ltd. 11-(2-pyrrolidin-1-YLethoxy)- 14,19-dioxa-5,7,26- triazatetracyclo[ 19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12 (27),16,21,23-decaene citrate salt. WO2010068181; 2010
99. S*BIO Pte Ltd. 11-(2-pyrrolidin-1-YLethoxy)- 14,19-dioxa-5,7,26- triazatetracyclo[ 19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12 (27),16,21,23-decaene maleate salt. WO2010068182; 2010
100. S*BIO Pte Ltd. 9E-15-(2-pyrrolidin-1- YL-ethoxy)-7,12,25-trioxa-19, 21,24- triaza-tetracyclo[18.3.1.1(2,5).1(14,18)] hexacosa-1(24),2,4,9,14,16,18 (26),20,22-nonaene citrate salt. WO2011008172; 2010
101. Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway. WO2012015972; 2012
102. Rigel Pharmaceuticals. Tricyclic carbamate JAK inhibitors. WO2010039518; 2010
103. Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway; 2). WO2010085684; 2010
104. Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway. WO2010075558; 2010
105. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21(8):1658-68
106. Targegen, Inc. Compositions and methods for treating myelofibrosis. WO2012061833; 2012
107. Targegen, Inc. Compositions and methods for treating myelofibrosis (2). WO2012060847; 2012
108. University of Florida Research Foundation, Inc. Kinase inhibitor compounds. WO2010068710; 2010
109. YM Biosciences Australia Pty Ltd. Multiple myeloma treatment. WO2012149602; 2012
110. YM Biosciences Australia Pty Ltd. Treatment of JAK2 mediated conditions. WO2012071612; 2012
111. Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as Janus kinase inhibitors (1). WO2011031554; 2011
112. Biocryst Pharmaceuticals, Inc. Pyrrolo [1,2-b]pyridazine derivatives as Janus kinase inhibitors. WO2011014817; 2011
113. Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as Janus kinase inhibitors (2). WO2011150356; 2011
114. Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as Janus kinase inhibitors (3). WO2011079230; 2011
115. Bristol-Myers Squibb Co. Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases. WO2012125887; 2012
116. Cellzome Ltd. Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors. WO2012022681; 2012
117. Cellzome Ltd. Pyrazole compounds as JAK inhibitors. WO2011134831; 2011
118. Cellzome Ltd. Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors. WO2011048082; 2011
119. Cellzome Ltd. Ortho substituted pyrimidine compounds as JAK inhibitors. WO2011029807; 2011
120. Dainippon Sumitomo Pharma. New azaindole derivatives. JP2012012332; 2012
121. Kowa Co., Ltd. Pyridine-3-carboxyamide derivative. WO2010061971; 2010
122. Portola Pharmaceuticals, Inc. Inhibitors of JAK. WO2010129802; 2010
123. Portola dual SYK-JAK inhibitor. Available from: http://www.portola.com/ PRT2070-Dual-SYK-JAK-Inhibitor [Last accessed November 2012]
124. Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators. US20120108566; 2012
125. F. Hoffmann-La Roche AG. Pyrrolopyrazine derivatives as SYK and JAK inhibitors. WO2011144584; 2011
126. F.Hoffman-La Roche AG. Pyrrolo[2,3-b] pyrazine-7-carboxamide derivatives and their uses as JAK and SYK inhibitors. WO2011144585; 2011
127. F.Hoffman-La Roche AG. Pyrrolopyrazinyl urea kinase inhibitors. WO2010063634; 2010
128. F.Hoffman-La Roche AG. Janus kinase inhibitor compounds and methods. WO2010142752; 2010
129. Takeda Pharmaceutical Co. Ltd. Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK. WO2010144486; 2010
130. Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions and medicinal applications thereof. WO2012127506; 2012
131. Almirall, SA. Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors. WO2012069202; 2012
132. Almirall, SA. Pyrazole derivatives as JAK inhibitors. WO2011101161; 2011
133. Almirall, SA. Imidazopyridine derivatives as JAK inhibitors. WO2011076419; 2011
134. Almirall, SA. Heteroaryl imidazole derivatives as JAK inhibitors. WO2011157397; 2011
135. Almirall, SA. Pyridine and isoquinoline derivatives as SYK- and JAK-kinase inhibitors. WO2012041476; 2012
136. Astellas Pharma, Inc. Fused pyrrolopyridine derivative. WO2010119875; 2010
137. Japan Tobacco, Inc. Nitrogen-containing spiro-ring compound and medicinal use of same. WO2011013785; 2011
138. Jiangsu Simcere. Large ring compound and application thereof. CN102617599; 2012
139. Leo Pharma A/S. Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof. WO2012003829; 2012
140. Leo Pharma A/S. Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors. WO2011003418; 2011
141. Merck Sharp & Dohme Corp. Bicyclic diamines as Janus kinase inhibitors. WO2012054364; 2012
142. Merck Sharp & Dohme Corp. Azaindoles as Janus kinase inhibitors. WO2011137022; 2011
143. Palau Pharma, SA. N-containing heteroaryl derivatives as JAK3 kinase inhibitors. WO2011051452; 2011
144. Palau Pharma, SA. Pyrazole[1,5-a] pyridine derivatives. WO2010072823; 2010
145. Andraos R, Qian Z, Bonenfant D, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov 2012;2(6):512-23
146. Alicea-Velazquez NL, Boggon TJ. The use of structural biology in Janus kinase targeted drug discovery. Curr Drug Targets 2011;12(4):546-55
147. Marit MR, Chohan M, Matthew N, et al. Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PloS One 2012;7(8):e43437
148. Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012;26(4):708-15
149. Ingley E, Klinken SP. Cross-regulation of JAK and Src kinases. Growth Factors 2006;24(1):89-95
150. Reilly JT. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma 2003;44(1):1-7
151. Younes A, Romaguera J, Fanale M, et al. Phase I. Study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012;30(33):4161-7
152. Novotny-Diermayr V, Hart S, Goh KC, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2012;2(5):e69
153. Panobinostat and Ruxolitinib in MPN clinical trial. 2011. Available from: http://clinicaltrials. gov/ct2/show/NCT01433445? term=ruxolitinib+and +panobinostat&rank=2 [Last accessed November 2012]
154. Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489(7414):155-9
155. AZD1480 Phase 1 study in solid tumors. 2010. Available from: http://clinicaltrials. gov/ct2/show/NCT01112397? term=AZD1480&rank=2 [Last accessed November 2012]
156. Maiga M, Lun S, Guo H, et al. Risk of tuberculosis reactivation with tofacitinib (CP-690550. J Infect Dis 2012;205(11):1705-8
157. Yoshida H, Kimura A, Fukaya T, et al. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochem Biophys Res Commun 2012;418(2):234-40
158. Migita K, Miyashita T, Izumi Y, et al. Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production. BMC Immunol 2011;12:51
159. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167(3):668-77
160. Vincenti F, Tedesco Silva H, Busque S, et al. Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: efficacy, Renal Function and Safety at 1 Year. Am J Transplant 2012;12(9):2446-56
161. Myrvang H. Transplantation: tofacitinib safe and effective in renal transplant recipients. Nat Rev Nephrol 2012;8(8):432
162. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367(7):616-24
163. Minturn JE, Evans AE, Villablanca JG, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol 2011;68(4):1057-65
164. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117(12):3294-301
165. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115(6):1131-6
166. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29(7):789-96
167. Lasho TL, Tefferi A, Hood JD, et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008;22(9):1790-2
168. Targegen, Inc. Biaryl meta pyrimidine inhibitors of kinases. US20110212077; 2011
169. SB1518 myelofibrosis clinical trial. 2008. Available from: http://clinicaltrials. gov/ct2/show/NCT00745550? term=SB1518&rank=1 [Last accessed November 2012]
170. SB1518 myelodysplastic Syndrome (MDS) clinical trial. Available from: http://clinicaltrials.gov/ct2/show/NCT01436084?term=SB1518&rank=5 [Last accessed November 2012]
171. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184(9):5298-307
172. Baricitinib in participants with diabetic kidney disease. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01683409?term=baricitinib&rank= 1 [Last accessed November 2012]
173. Monaghan KA, Khong T, Burns CJ, Spencer A. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 2011;25(12):1891-9
174. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115(25):5232-40
175. Ioannidis S, Lamb ML, Wang T, et al. Discovery of 5-chloro-N2-[(1S)-1-(5- fluoropyrimidin-2-yl)ethyl]-N4-(5- methyl-1H-pyrazol-3-yl)p yrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. J Med Chem 2011;54(1):262-76
176. Xin H, Herrmann A, Reckamp K, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res 2011;71(21):6601-10
177. AZD1480 clinical trial. 2010. Available from: http://clinicaltrials. gov/ct2/show/NCT01112397? term=AZD1480&rank=2 [Last accessed November 2012]
178. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16(6):487-97
179. McFarland BC, Ma JY, Langford CP, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 2011;10(12):2384-93
180. Madan B, Goh KC, Hart S, et al. SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis. J Immunol 2012;189(8):4123-34
181. SB1578 clinical trial. 2011. Available from: http://clinicaltrials. gov/ct2/show/NCT01235871? term=1578&rank=1 [Last accessed November 2012]
182. LY2784544 myeloproliferative neoplasms clinical trial. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01594723? term=LY2784544&rank=3 [Last accessed November 2012]
183. Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J 2011;1(7):e29
184. NS-018 oral clinical trial in MPN patients. 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01423851?term=NS-018&rank=1 [Last accessed November 2012]
185. VX-509 clinical trial in RA in subject taking methotrexate. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01590459?term=VX- 509&rank=2 [Last accessed November 2012]
186. GSK2586184 Phase 1 trial. 2012. Available from: http://clinicaltrials. gov/ct2/show/NCT01687309? term=GSK2586184&rank=1 [Last accessed November 2012]
187. GLPG0634 in methotrexate-refractory rheumatoid arthritis patients. 2011. Available from: http://clinicaltrials. gov/ct2/show/NCT01384422? term=GLPG-0634&rank=5 [Last accessed November 2012]
188. Two clinical posters on GLPG-0634. 2012. Available from: http://www.glpg. com/index.php/randd/pipeline/glpg0634- ra/[Last accessed November 2012]